ScripThe dominos fell as expected in the non-alcoholic steatohepatitis (NASH) R&D space as Intercept Pharmaceuticals, Inc. announced late on 22 June that it had received a second complete response letter
ScripThe turn of the year witnessed a spike in venture capital and private equity funding deals in China, with several valued at around the $100m level. A string of four large financings around late Decemb
ScripCoya Therapeutics, Inc. launched the final biopharmaceutical initial public offering in the US in 2022 on 29 December, raising $15.25m from the sale of 3.05 million shares at $5 each, which brought t